215 related articles for article (PubMed ID: 34518311)
61. Dichotomous effects of cellular expression of STAT3 on tumor growth of HNSCC.
Bickett TE; Knitz MW; Piper M; Oweida AJ; Gadwa J; Darragh LB; Nguyen D; Bhatia S; Bhuvane S; Phan AV; Van Court B; Corbo S; Pham T; Dent AL; Lenz L; Karam SD
Mol Ther; 2022 Mar; 30(3):1149-1162. PubMed ID: 34793974
[TBL] [Abstract][Full Text] [Related]
62. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
[TBL] [Abstract][Full Text] [Related]
63. Mechanisms of bacillus Calmette-Guerin mediated natural killer cell activation.
Suttmann H; Jacobsen M; Reiss K; Jocham D; Böhle A; Brandau S
J Urol; 2004 Oct; 172(4 Pt 1):1490-5. PubMed ID: 15371877
[TBL] [Abstract][Full Text] [Related]
64. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
[TBL] [Abstract][Full Text] [Related]
65. Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA.
Kundu K; Ghosh S; Sarkar R; Edri A; Brusilovsky M; Gershoni-Yahalom O; Yossef R; Shemesh A; Soria JC; Lazar V; Joshua BZ; Campbell KS; Elkabets M; Porgador A
Cancer Immunol Res; 2019 Jul; 7(7):1120-1134. PubMed ID: 31164357
[TBL] [Abstract][Full Text] [Related]
66. The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
Bisheshar SK; De Ruiter EJ; Devriese LA; Willems SM
Oncoimmunology; 2020; 9(1):1747345. PubMed ID: 32363116
[No Abstract] [Full Text] [Related]
67. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
Ghiringhelli F; Ménard C; Terme M; Flament C; Taieb J; Chaput N; Puig PE; Novault S; Escudier B; Vivier E; Lecesne A; Robert C; Blay JY; Bernard J; Caillat-Zucman S; Freitas A; Tursz T; Wagner-Ballon O; Capron C; Vainchencker W; Martin F; Zitvogel L
J Exp Med; 2005 Oct; 202(8):1075-85. PubMed ID: 16230475
[TBL] [Abstract][Full Text] [Related]
68. Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer.
Iyoda T; Yamasaki S; Ueda S; Shimizu K; Fujii SI
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830717
[TBL] [Abstract][Full Text] [Related]
69. In vitro tumor-pulsed or in vivo Flt3 ligand-generated dendritic cells provide protection against acute myelogenous leukemia in nontransplanted or syngeneic bone marrow-transplanted mice.
Pawlowska AB; Hashino S; McKenna H; Weigel BJ; Taylor PA; Blazar BR
Blood; 2001 Mar; 97(5):1474-82. PubMed ID: 11222396
[TBL] [Abstract][Full Text] [Related]
70. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
Niu G; Sun X; Cao Q; Courter D; Koong A; Le QT; Gambhir SS; Chen X
Clin Cancer Res; 2010 Apr; 16(7):2095-105. PubMed ID: 20215534
[TBL] [Abstract][Full Text] [Related]
71. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
72. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients.
Srivastava RM; Lee SC; Andrade Filho PA; Lord CA; Jie HB; Davidson HC; López-Albaitero A; Gibson SP; Gooding WE; Ferrone S; Ferris RL
Clin Cancer Res; 2013 Apr; 19(7):1858-72. PubMed ID: 23444227
[TBL] [Abstract][Full Text] [Related]
73. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.
Schilling B; Halstead ES; Schuler P; Harasymczuk M; Egan JE; Whiteside TL
Cancer Immunol Immunother; 2012 Sep; 61(9):1395-405. PubMed ID: 22270713
[TBL] [Abstract][Full Text] [Related]
74. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
75. NK Cell Anti-Tumor Surveillance in a Myeloid Cell-Shaped Environment.
Russo E; Laffranchi M; Tomaipitinca L; Del Prete A; Santoni A; Sozzani S; Bernardini G
Front Immunol; 2021; 12():787116. PubMed ID: 34975880
[TBL] [Abstract][Full Text] [Related]
76. In vivo Anti-Cancer Effects of Resveratrol Mediated by NK Cell Activation.
Lee Y; Shin H; Kim J
J Innate Immun; 2021; 13(2):94-106. PubMed ID: 32937636
[TBL] [Abstract][Full Text] [Related]
77. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients.
Trivedi S; Srivastava RM; Concha-Benavente F; Ferrone S; Garcia-Bates TM; Li J; Ferris RL
Clin Cancer Res; 2016 Nov; 22(21):5229-5237. PubMed ID: 27217441
[TBL] [Abstract][Full Text] [Related]
78. Downregulation of AT-rich interaction domain 2 underlies natural killer cell dysfunction in oral squamous cell carcinoma.
Li W; An N; Wang M; Liu X; Mei Z
Immunol Cell Biol; 2023 Jan; 101(1):78-90. PubMed ID: 36269235
[TBL] [Abstract][Full Text] [Related]
79. ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.
Konno H; Lin T; Wu R; Dai X; Li S; Wang G; Chen M; Li W; Wang L; Sun BC; Luo Z; Huang T; Chen Y; Zhang J; Ye Q; Bellovin D; Wan B; Kang L; Szeto C; Hsu K; Kabbarah O
Cancer Res Commun; 2022 Sep; 2(9):937-950. PubMed ID: 36922936
[TBL] [Abstract][Full Text] [Related]
80. IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity.
Bose A; Baral R
Immunol Lett; 2007 Jan; 108(1):68-77. PubMed ID: 17112599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]